@article{8194f591fee341ccb08cfc88122fbdf5,
title = "Final Report of NRG Oncology RTOG 0022: A Phase 1/2 Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer",
author = "Garden, \{Adam S.\} and Jonathan Harris and Avraham Eisbruch and Chao, \{K. S.Clifford\} and Morrison, \{William H.\} and Harari, \{Paul M.\} and Swanson, \{Todd Allen\} and Jones, \{Christopher U.\} and Yom, \{Sue S.\} and Spencer, \{Sharon A.\} and Rufus Scrimger and George Shenouda and Monica Shukla and Lau, \{Harold Y.\} and Michelle Mierzwa and Pedro Torres-Saavedra and Le, \{Quynh Thu\}",
note = "Funding Information: Disclosures: Q.T.L. reports support for attending meetings and/or travel from the Radiation Therapy Oncology Group (RTOG) Foundation and a leadership role as RTOG group chair (NRG Oncology). M.M. reports that Bristol-Myers Squibb supplied drugs for clinical trial UMCC 2018.085. In addition, she received academic support from Debio and holds a leadership role with the International Journal of Radiation Oncology • Biology • Physics as associate editor for the head and neck section. P.T.-S. reports support for the present article from NRG Oncology SDMC and the grant from the National Cancer Institute. S.S.Y. reports grants or contracts paid to her institution for research support from Genentech, BioMimetix, Merck, EMD Serono, and Bristol-Myers Squibb; royalties or licenses from UpToDate and Springer; and payment or honoraria for lectures or presentations from the American Society for Radiation Oncology and Elsevier. She is also a past president of the American Radium Society. The remaining authors have no disclosures to report. Funding Information: This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology Statistical and Data Management Center), and U24CA180803 (Imaging and Radiation Oncology Center) from the National Cancer Institute. Disclosures: Q.T.L. reports support for attending meetings and/or travel from the Radiation Therapy Oncology Group (RTOG) Foundation and a leadership role as RTOG group chair (NRG Oncology). M.M. reports that Bristol-Myers Squibb supplied drugs for clinical trial UMCC 2018.085. In addition, she received academic support from Debio and holds a leadership role with the International Journal of Radiation Oncology • Biology • Physics as associate editor for the head and neck section. P.T.-S. reports support for the present article from NRG Oncology SDMC and the grant from the National Cancer Institute. S.S.Y. reports grants or contracts paid to her institution for research support from Genentech, BioMimetix, Merck, EMD Serono, and Bristol-Myers Squibb; royalties or licenses from UpToDate and Springer; and payment or honoraria for lectures or presentations from the American Society for Radiation Oncology and Elsevier. She is also a past president of the American Radium Society. The remaining authors have no disclosures to report.",
year = "2023",
month = oct,
day = "1",
doi = "10.1016/j.ijrobp.2023.02.057",
language = "English (US)",
volume = "117",
pages = "333--340",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",
}